January 2008
BioWorld Today;1/11/2008, Vol. 19 Issue 8, p4
This section offers news briefs related to patent disclosures in the U.S. Avicena Group Inc. in Palo Alto, California, has received a patent that covers the use of the company's drug candidates against amyotrophic lateral sclerosis. CellCyte Genetics Corp. in Kirkland, Washington, has received a patent that covers methods and compositions for delivering and directing stem cells to target organs in the body. CytoGenix Inc. in Houston, Texas, has received a notice of allowance for a patent on its herpes composition.


Related Articles

  • FDA GRANTS AVICENA ORPHAN-DRUG DESIGNATION FOR CREATINE.  // Biotech Business;May2002, Vol. 15 Issue 5, p4 

    Presents information on the Orphan-Drug Designation given by the U.S. Food and Drug Administration to biotechnology company The Avicena Group, Inc. to treat Amyotrophic Lateral Sclerosis (ALS) with creatine. Functions of creatine; Description of ALS; Operational background of Avicena.

  • Support services important component of Rilutek launch. Rodgers, Katie // Drug Topics;2/5/96, Vol. 140 Issue 3, p46 

    Reports on the planned launch of Rhone-Poulenc Rhorer's (RPR) Rilutek riluzole drug for amyotrophic lateral sclerosis (ALS). Patient support services; Background information; Implications; Plans and expectations.

  • Understanding Lou Gehrig's disease.  // Patient Care;2/28/1997, Vol. 31 Issue 4, p16 

    Reports on the nationwide program to develop guidelines for the treatment of amyotyhrophic lateral sclerosis (ALS) in the United States. Prevalence of ALS in the country; Contact information for physicians and patients interested to participate in the program.

  • A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis. Bensimon, G.; Lacomblez, L.; Meininger, V. // New England Journal of Medicine;3/3/94, Vol. 330 Issue 9, p585 

    Background: Amyotrophic lateral sclerosis is a progressive motor neuron disease for which there is no adequate treatment. Some research suggests that the excitatory amino acid neurotransmitter glutamate may be involved in the pathogenesis. Methods: To evaluate the efficacy and safety of the...

  • ALS drug slows progression. Rodgers, Katie // Drug Topics;11/20/95, Vol. 139 Issue 22, p52 

    Reports on the findings of a phase III clinical trial presented at the SiSixt International Symposium on amyotrophic lateral sclerosis.motor neuron disease.

  • Nerve preserver. Munson, Marty; Higbee, Beth // Prevention;Nov95, Vol. 47 Issue 11, p58 

    Reports on the results of a pilot study on a drug used for staving off the crippling effects of Lou Gehrig's disease or amyotrophic lateral sclerosis published in the March 3, 1994 issue of the `New England Journal of Medicine'. Possibility of a prolonged survival; Availability of other...

  • ALS guidelines.  // Drug Topics;12/9/96, Vol. 140 Issue 23, p32 

    Reports on the creation of the Amyotrophic Lateral Sclerosis Clinical Assessment, Research and Education (CARE) Program to study practice patterns and treatment guidelines. Funding from Rhone-Poulenc Rorer; Goal of improving treatment and quality of life of patients.

  • Combination approach may be key to Lou Gehrig's disease. Henahan, Sean // Drug Topics;5/6/96, Vol. 140 Issue 9, p78 

    Reports that a combination of three putative pathways of the pathogenesis of amyotrophic lateral sclerosis is provided researchers with promising therapeutic strategies for the disease, also known as Lou Gehrig's Disease. Causes of neural degeneration; Therapeutic properties of riluzole and...

  • Update on amyotrophic lateral sclerosis. R.M.D. // Cortlandt Forum;11/25/96, Vol. 9 Issue 11, p121 

    Responds to an inquiry regarding recommended treatment for amyotrophic lateral sclerosis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics